Alkermes drug gets fast-track status; FDA's Woodcock staying put; Opioid-induced constipation market taking off;

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@EricPFierce:  spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce

@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce

> Alkermes ($ALKS) says the FDA has granted fast-track status for its experimental medicine to combat depression, intended for patients who don't respond to standard therapies. Report

> The U.K.'s Association of the British Pharmaceutical Industry (ABPI) is taking a look at its code of practice for drugmakers in the U.K. and expects to recommend changes for an update slated for January 2015. Story

> Janet Woodcock, director of the the FDA's Center for Drug Evaluation and Research (CDER), sent a memo to agency staff saying she has no plans to retire after a Reuters story pointed out she was nearing an age when she might. Story | More from FierceBiotech

> GlaxoSmithKline ($GSK) has opened what it refers to as the Human Performance Lab for researching how the body is fueled, boosting health and understanding keys to longevity. Story

> The FDA says it is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking Ariad's ($ARIA) leukemia chemotherapy drug Iclusig (ponatinib). Release

Medical Device News

@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> St. Jude Medical CEO knocks rival and regulatory climate, but also offers optimism. More

> Gov't shutdown halts FCC's wireless med tech certification. Item

> Bipartisan backing of device tax repeal threatened by gov't funding fight. Story

> German-U.S. team test intestinal tube implant to treat obesity. Article

Biotech News

@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce

@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce

@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce

> Celladon, Xencor bid for $155M in red-hot IPO market. Story

> Researchers hit Alzheimer's 'turning point' with new target. Article

> MacroGenics shares soar on glittering $80M IPO debut. Report

And Finally... GlobalData claims the opioid-induced constipation (OIC) global market will post nearly a 32% compound annual growth rate and hit $1.98 billion by 2017, up from just $144.42 million in 2012. Release

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.